Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.42 per share a year ago.
Will Profound Medical (PROF) Report Negative Earnings Next Week? What You Should Know
Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Profound Medical Corporation (PROF) Q3 2024 Earnings Call Transcript
Profound Medical Corporation (NASDAQ:PROF ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat - CEO Rashed Dewan - CFO Mathieu Burtnyk - COO Conference Call Participants Benjamin Haynor - Lake Street Capital Markets John Baugh - Stifel Michael Freeman - Raymond James Scott McAuley - Paradigm Capital Operator Good day and thank you for standing by. Welcome to the Profound Medical Third Quarter 2024 Financial Results Conference Call.
Profound Medical (PROF) Reports Q3 Loss, Lags Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.26 per share a year ago.
Wall Street Analysts Predict a 106.45% Upside in Profound Medical (PROF): Here's What You Should Know
The consensus price target hints at a 106.5% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Profound Medical (PROF) Moves 5.1% Higher: Will This Strength Last?
Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Profound Medical Corporation (PROF) Q2 2024 Earnings Call Transcript
Profound Medical Corporation (NASDAQ:PROF ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat - CEO Rashed Dewan - CFO Mathieu Burtnyk - COO Conference Call Participants Rick Wise - Stifel Ben Haynor - Lake Street Capital Markets Rahul Sarugaser - Raymond James Michael Sarcone - Jefferies Scott McAuley - Paradigm Capital Brian Gagno - Gagnon Securities Operator Welcome to the Profound Medical Second Quarter 2024 Financial Results conference call. [Operator Instructions].
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.35 per share a year ago.
Profound Medical (PROF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Profound Medical (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Profound Medical (PROF) Surges 6.0%: Is This an Indication of Further Gains?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Profound Medical (PROF) Adds AI to Prostate Cancer Treatment
Profound Medical's (PROF) Contouring Assistant integrates AI into prostate cancer procedures, thereby streamlining the treatment planning process and enhancing both efficiency and precision.
